Bolt Biotherapeutics Analyst Ratings
Bolt Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 520.16% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 08/03/2023 | 520.16% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 06/05/2023 | 520.16% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/26/2023 | 520.16% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 05/12/2023 | 210.08% | SVB Leerink | → $4 | Upgrades | Market Perform → Outperform |
| 05/12/2023 | 520.16% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 03/30/2023 | 520.16% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 01/24/2023 | 132.56% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 10/04/2022 | 520.16% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
| 08/11/2022 | 210.08% | SVB Leerink | $8 → $4 | Downgrades | Outperform → Market Perform |
| 05/17/2022 | 287.6% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/06/2022 | 752.71% | Morgan Stanley | $45 → $11 | Downgrades | Overweight → Equal-Weight |
| 11/10/2021 | 2458.14% | SVB Leerink | $35 → $33 | Maintains | Outperform |
| 08/16/2021 | 2613.18% | SVB Leerink | $34 → $35 | Maintains | Outperform |
| 05/17/2021 | 2458.14% | SVB Leerink | $37 → $33 | Maintains | Outperform |
| 04/06/2021 | 2768.22% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 03/02/2021 | 3000.78% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 03/02/2021 | 3155.81% | Guggenheim | → $42 | Initiates Coverage On | → Buy |
| 03/02/2021 | 3388.37% | Morgan Stanley | → $45 | Initiates Coverage On | → Overweight |
| 03/02/2021 | 2690.7% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/08/08 | 520.16% | HC Wainwright公司 | →$8 | 重申 | 購買→購買 |
| 08/03/2023 | 520.16% | HC Wainwright公司 | →$8 | 重申 | →購買 |
| 06/05/2023 | 520.16% | HC Wainwright公司 | →$8 | 重申 | 購買→購買 |
| 2023年05月26日 | 520.16% | HC Wainwright公司 | →$8 | 重申 | →購買 |
| 2023年05月12日 | 210.08% | SVB Leerink | →$4 | 升級 | 市場表現優於→ |
| 2023年05月12日 | 520.16% | HC Wainwright公司 | →$8 | 重申 | 購買→購買 |
| 03/30/2023 | 520.16% | HC Wainwright公司 | →$8 | 重申 | →購買 |
| 01/24/2023 | 132.56% | 摩根士丹利 | $5→$3 | 維護 | 等重 |
| 10/04/2022 | 520.16% | HC Wainwright公司 | →$8 | 開始承保 | →購買 |
| 2022年08月11日 | 210.08% | SVB Leerink | $8→$4 | 評級下調 | 跑贏→市場表現 |
| 2022/05/17 | 287.6% | 摩根士丹利 | $7→$5 | 維護 | 等重 |
| 01/06/2022 | 752.71% | 摩根士丹利 | $45→$11 | 評級下調 | 超重→等重 |
| 2021年11月10日 | 2458.14% | SVB Leerink | $35→$33 | 維護 | 跑贏大盤 |
| 08/16/2021 | 2613.18% | SVB Leerink | $34→$35 | 維護 | 跑贏大盤 |
| 2021/05/17 | 2458.14% | SVB Leerink | $37→$33 | 維護 | 跑贏大盤 |
| 04/06/2021 | 2768.22% | SVB Leerink | $36→$37 | 維護 | 跑贏大盤 |
| 03/02/2021 | 3000.78% | Stifel | →$40 | 開始承保 | →購買 |
| 03/02/2021 | 3155.81% | 古根海姆 | →$42 | 開始承保 | →購買 |
| 03/02/2021 | 3388.37% | 摩根士丹利 | →$45 | 開始承保 | →超重 |
| 03/02/2021 | 2690.7% | SVB Leerink | →$36 | 開始承保 | →跑贏大盤 |
What is the target price for Bolt Biotherapeutics (BOLT)?
博爾特生物療法(Bolt)的目標價是多少？
The latest price target for Bolt Biotherapeutics (NASDAQ: BOLT) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $8.00 expecting BOLT to rise to within 12 months (a possible 520.16% upside). 10 analyst firms have reported ratings in the last year.
博爾特生物治療公司(納斯達克代碼：BOLT)的最新目標價是由HC Wainwright&Co.於2023年8月8日報道的。這家分析公司將目標價定為8美元，預計博爾特將在12個月內上漲(可能上漲520.16%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Bolt Biotherapeutics (BOLT)?
博爾特生物治療公司(Bolt)的最新分析師評級是多少？
The latest analyst rating for Bolt Biotherapeutics (NASDAQ: BOLT) was provided by HC Wainwright & Co., and Bolt Biotherapeutics reiterated their buy rating.
博爾特生物治療公司(納斯達克代碼：BOLT)的最新分析師評級由HC Wainwright&Co.提供，博爾特生物治療公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Bolt Biotherapeutics (BOLT)?
博爾特生物療法(Bolt)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bolt Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bolt Biotherapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Bolt BioTreateutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Bolt BioTreateutics的上一次評級是在2023年8月8日提交的，所以你應該預計下一次評級將在2024年8月8日左右提供。
Is the Analyst Rating Bolt Biotherapeutics (BOLT) correct?
分析師對Bolt BioTreateutics(Bolt)的評級正確嗎？
While ratings are subjective and will change, the latest Bolt Biotherapeutics (BOLT) rating was a reiterated with a price target of $0.00 to $8.00. The current price Bolt Biotherapeutics (BOLT) is trading at is $1.29, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Bolt BioTreateutics(Bolt)評級被重申，目標價在0.00美元至8.00美元之間。博爾特生物治療公司(Bolt)目前的交易價格為1.29美元，在分析師的預測範圍內。